Skip to content

Study · Non-randomized trial · n = 14 · 2019

3 results

Urinary mitochondrial DNA copy number identifies renal mitochondrial injury in renovascular hypertensive patients undergoing renal revascularization: A Pilot Study.

Eirin A, Herrmann SM, Saad A, Abumoawad A, Tang H, Lerman A, Textor SC, Lerman LO

Acta physiologica (Oxford, England)13 Mar 2019Cited by 21 (Europe PMC)

PMID30803138 (opens in a new tab)PMCIDPMC6556125 (opens in a new tab)DOI10.1111/apha.13267 (opens in a new tab)PepBankPUB-30803138
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialMechanism

    In patients with renovascular hypertension undergoing renal angioplasty, elamipretide infusion blunted the rise in urinary mtDNA at 24 hours compared with placebo.

    In plain wordsIn patients with renovascular hypertension having a kidney procedure, elamipretide reduced the rise in a kidney injury marker in urine more than placebo.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseUrinary mtDNA rise 24 hours after PTRA
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.05 mg/kg/h · intravenousAs given in this study (human).

    Source sentences

    Summary
    An increase in urinary mtDNA 24 hours after PTRA was blunted in PTRA+ELAM vs PTRA+Placebo.
    1 context sentence
    Summary · context
    We prospectively measured urinary copy number of the mtDNA genes COX3 and ND1 using qPCR in RVH patients before and 24 hrs after PTRA, performed during IV infusion of vehicle (n = 8) or the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/h, n = 6).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with renovascular hypertension, systolic blood pressure decreased 3 months after angioplasty only in elamipretide-treated patients.

    In plain wordsIn patients with renovascular hypertension, systolic blood pressure fell 3 months after the procedure only in those who received elamipretide.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseSystolic blood pressure 3 months after PTRA
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.05 mg/kg/h · intravenousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, 3-months after PTRA, systolic blood pressure decreased and estimated glomerular filtration rate increased only in ELAM-treated subjects.
    1 context sentence
    Summary · context
    We prospectively measured urinary copy number of the mtDNA genes COX3 and ND1 using qPCR in RVH patients before and 24 hrs after PTRA, performed during IV infusion of vehicle (n = 8) or the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/h, n = 6).
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with renovascular hypertension, estimated glomerular filtration rate increased 3 months after angioplasty only in elamipretide-treated patients.

    In plain wordsIn patients with renovascular hypertension, kidney filtration rate rose 3 months after the procedure only in those who received elamipretide.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseEstimated GFR 3 months after PTRA
    Study

    n = 14

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.05 mg/kg/h · intravenousAs given in this study (human).

    Source sentences

    Summary
    Furthermore, 3-months after PTRA, systolic blood pressure decreased and estimated glomerular filtration rate increased only in ELAM-treated subjects.
    1 context sentence
    Summary · context
    We prospectively measured urinary copy number of the mtDNA genes COX3 and ND1 using qPCR in RVH patients before and 24 hrs after PTRA, performed during IV infusion of vehicle (n = 8) or the mitoprotective drug elamipretide (ELAM, 0.05 mg/kg/h, n = 6).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.